Literature DB >> 33925681

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms.

Laura Palomo1,2, Pamela Acha1, Francesc Solé1.   

Abstract

Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are myeloid neoplasms characterized by the presentation of overlapping features from both myelodysplastic syndromes and myeloproliferative neoplasms. Although the classification of MDS/MPN relies largely on clinical features and peripheral blood and bone marrow morphology, studies have demonstrated that a large proportion of patients (~90%) with this disease harbor somatic mutations in a group of genes that are common across myeloid neoplasms. These mutations play a role in the clinical heterogeneity of these diseases and their clinical evolution. Nevertheless, none of them is specific to MDS/MPN and current diagnostic criteria do not include molecular data. Even when such alterations can be helpful for differential diagnosis, they should not be used alone as proof of neoplasia because some of these mutations may also occur in healthy older people. Here, we intend to review the main genetic findings across all MDS/MPN overlap syndromes and discuss their relevance in the management of the patients.

Entities:  

Keywords:  cytogenetics; gene mutations; molecular landscape; myelodysplastic/myeloproliferative neoplasms

Year:  2021        PMID: 33925681     DOI: 10.3390/cancers13092120

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  101 in total

1.  Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients.

Authors:  Abhishek A Mangaonkar; David M Swoboda; Giacomo Coltro; Terra L Lasho; Paul J Novotny; Prateek Pophali; Ryan M Carr; Moritz Binder; Christy M Finke; Naseema Gangat; Aref Al-Kali; Kebede H Begna; Kaaren K Reichard; Rhett P Ketterling; Najla H Al Ali; Pardis Vafaii; Ling Zhang; Eric Padron; Chetasi Talati; Mrinal M Patnaik
Journal:  Leukemia       Date:  2019-09-11       Impact factor: 11.528

2.  Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS).

Authors:  Iván Martín; Esperanza Such; Blanca Navarro; Ana Vicente; María López-Pavía; Mariam Ibáñez; Mar Tormo; Eva Villamón; Inés Gómez-Seguí; Irene Luna; Silvestre Oltra; Laia Pedrola; Miguel Angel Sanz; Jose Cervera; Guillermo Sanz
Journal:  Leuk Lymphoma       Date:  2016-10-24

3.  Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management.

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2020-01       Impact factor: 10.047

4.  Genomic determinants of chronic myelomonocytic leukemia.

Authors:  B J Patel; B Przychodzen; S Thota; T Radivoyevitch; V Visconte; T Kuzmanovic; M Clemente; C Hirsch; A Morawski; R Souaid; C Saygin; A Nazha; B Demarest; T LaFramboise; H Sakaguchi; S Kojima; H E Carraway; S Ogawa; H Makishima; M A Sekeres; J P Maciejewski
Journal:  Leukemia       Date:  2017-05-30       Impact factor: 11.528

5.  Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations.

Authors:  Yuka Sugimoto; Hideki Muramatsu; Hideki Makishima; Courtney Prince; Anna M Jankowska; Nao Yoshida; Yinyan Xu; Nobuhiro Nishio; Asahito Hama; Hiroshi Yagasaki; Yoshiyuki Takahashi; Koji Kato; Atsushi Manabe; Seiji Kojima; Jaroslaw P Maciejewski
Journal:  Br J Haematol       Date:  2010-04-12       Impact factor: 6.998

6.  Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.

Authors:  Esther A Obeng; Ryan J Chappell; Michael Seiler; Michelle C Chen; Dean R Campagna; Paul J Schmidt; Rebekka K Schneider; Allegra M Lord; Lili Wang; Rutendo G Gambe; Marie E McConkey; Abdullah M Ali; Azra Raza; Lihua Yu; Silvia Buonamici; Peter G Smith; Ann Mullally; Catherine J Wu; Mark D Fleming; Benjamin L Ebert
Journal:  Cancer Cell       Date:  2016-09-12       Impact factor: 31.743

Review 7.  The genetic basis of myelodysplasia and its clinical relevance.

Authors:  Mario Cazzola; Matteo G Della Porta; Luca Malcovati
Journal:  Blood       Date:  2013-10-17       Impact factor: 22.113

8.  Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features.

Authors:  Xavier Calvo; Nieves Garcia-Gisbert; Ivonne Parraga; Joan Gibert; Lourdes Florensa; Marcio Andrade-Campos; Brayan Merchan; Sara Garcia-Avila; Sara Montesdeoca; Concepción Fernández-Rodríguez; Marta Salido; Anna Puiggros; Blanca Espinet; Luís Colomo; David Roman-Bravo; Beatriz Bellosillo; Ana Ferrer; Leonor Arenillas
Journal:  Blood Adv       Date:  2020-10-27

9.  Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.

Authors:  Jane Merlevede; Nathalie Droin; Tingting Qin; Kristen Meldi; Kenichi Yoshida; Margot Morabito; Emilie Chautard; Didier Auboeuf; Pierre Fenaux; Thorsten Braun; Raphael Itzykson; Stéphane de Botton; Bruno Quesnel; Thérèse Commes; Eric Jourdan; William Vainchenker; Olivier Bernard; Noemie Pata-Merci; Stéphanie Solier; Velimir Gayevskiy; Marcel E Dinger; Mark J Cowley; Dorothée Selimoglu-Buet; Vincent Meyer; François Artiguenave; Jean-François Deleuze; Claude Preudhomme; Michael R Stratton; Ludmil B Alexandrov; Eric Padron; Seishi Ogawa; Serge Koscielny; Maria Figueroa; Eric Solary
Journal:  Nat Commun       Date:  2016-02-24       Impact factor: 14.919

10.  Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.

Authors:  Sophie Vantyghem; Pierre Peterlin; Sylvain Thépot; Audrey Ménard; Viviane Dubruille; Camille Debord; Thierry Guillaume; Alice Garnier; Amandine Le Bourgeois; Soraya Wuilleme; Catherine Godon; Olivier Theisen; Marion Eveillard; Jacques Delaunay; Hervé Maisonneuve; Nadine Morineau; Bruno Villemagne; Stéphane Vigouroux; François Subiger; Elsa Lestang; Marion Loirat; Anne Parcelier; Pascal Godmer; Mélanie Mercier; Adrien Trebouet; Damien Luque Paz; Ronan Le Calloch; Lenaig Le Clech; Céline Bossard; Anne Moreau; Valérie Ugo; Mathilde Hunault; Philippe Moreau; Steven Le Gouill; Patrice Chevallier; Marie C Béné; Yannick Le Bris
Journal:  Haematologica       Date:  2021-03-01       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.